FMI Research Offers 10-Year Forecast on Depression And | Page 5

Depression And Seasonal Affective Disorder Therapeutics Market
manufacture of more efficient drugs for the treatment of depression and seasonal affective disorder also
responsible for the rapid of this market. The increasing awareness among the people about seasonal
affective disorder will propel the growth of this market in developing countries. Favorable reimbursement
scenario and more improved distribution network in developed countries will boost the growth of
depression and seasonal affective disorder therapeutics market. The growing market for generic drugs
and more preference of patient for light therapy will hinder the growth of depression and seasonal
affective disorder therapeutics market. The patent expiry for the majority of the drugs and several side
effect by consumption of anti-depressant can also restraint the growth of depression and seasonal
affective disorder therapeutics market.
Request Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-3071
Depression and Seasonal Affective Disorder Therapeutics Market: Overview
Depression and seasonal affective disorder therapeutics market is expected to show substantial growth
over the forecast period. According to survey published in SAGE Publication, 10 % of U.S. population
suffers from the seasonal affective disorder. Depression and seasonal affective disorder therapeutics
market can be classified on the basis of drug therapy and distribution channel. Based on depression and
seasonal affective disorder therapeutics market is classified as selective serotonin reuptake inhibitors,
norepinephrine-dopamine reuptake inhibitor, serotonin and norepinephrine reuptake inhibitors,
monoamine oxidase inhibitors, tricyclic antidepressants and other. The selective serotonin reuptake
inhibitors are expected to dominate the major market in term of value over the forecast period. The
©2015 Future Market Insights, All Rights Reserved
5